Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/GSK Levitra Has 16% Share Of New Scripts; 2003 Sales Reach $180 Mil.

Executive Summary

Bayer/GlaxoSmithKline's Levitra has a 16% share of new prescriptions in the erectile dysfunction disorder market, Bayer CFO Klaus Kuhn reported during a year-end investor meeting March 18

You may also be interested in...



Cialis, Levitra market share numbers

Lilly/Icos' erectile dysfunction therapy Cialis is tracking approximately three percentage points ahead of Bayer/GlaxoSmithKline's Levitra, Lilly said. Lilly reported that for the week ending March 12, Cialis (tadalafil) captured 18.1% of new prescriptions while Levitra (vardenafil) held a 15.4% share. Bayer reported new Rx market share of 16% during its year-end investor meeting March 18 (1"The Pink Sheet" March 22, 2004, p. 27). Both agents are in a head-to-head battle to overtake Pfizer's Viagra, which remains the market leader...

Cialis, Levitra market share numbers

Lilly/Icos' erectile dysfunction therapy Cialis is tracking approximately three percentage points ahead of Bayer/GlaxoSmithKline's Levitra, Lilly said. Lilly reported that for the week ending March 12, Cialis (tadalafil) captured 18.1% of new prescriptions while Levitra (vardenafil) held a 15.4% share. Bayer reported new Rx market share of 16% during its year-end investor meeting March 18 (1"The Pink Sheet" March 22, 2004, p. 27). Both agents are in a head-to-head battle to overtake Pfizer's Viagra, which remains the market leader...

Bayer Layoffs, Spin-Offs Will Leave “Mid-Sized” European Company

Bayer is comfortable being a mid-sized European pharmaceutical company

Related Content

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel